Wugen Raises $172 Million To Advance Clinical Stage Memory Nk Cell Platform, Progress Best-In-Class Aml Program, And Initiate Multiple Solid Tumor Trials
Amount Raised
$172 Million
Round Type
Funding Round
St. LouisBiotechnologyresearchDescription
Wugen, Inc., a clinical stage biotechnology company developing a pipeline of off-the-shelf cell therapies, today announced the completion of an oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management & Research Company, Intermediate Capital Group (ICG), Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital. Existing investors, including RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital, also participated. In connection with the financing, Bali Muralidhar, M.D., Ph.D., Managing Partner at Abingworth, Bosun Hau, Managing Director at Tybourne Capital Management, and Peter Kiener, Ph.D., Venture Partner at ICG, will join Wugen’s Board of Directors. The proceeds of the financing will support further clinical development of Wugen’s best-in-class memory natural killer (NK) cell platform and advance ongoing trials for patients with severe acute myelogenous leukemia (AML) and other oncology indications, including solid tumors
Quick answer
Wugen raised $172 Million in a Funding Round round, dated July 15, 2021. Wugen is based in St. Louis, Missouri, United States.
- How much did Wugen raise?
- Wugen raised $172 Million in a Funding Round round on July 15, 2021.
- What does Wugen do?
- Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.
- Where is Wugen based and how big is it?
- Wugen is based in St. Louis, Missouri, United States. Fundz records about 58 employees.
- Who are the decision-makers at Wugen?
- Fundz holds 1 contact at Wugen. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in research and Biotechnology around the same time
Companies in the same sectors as Wugen that raised within 45 days of this round, from Fundz verified event records.
- Linnaeus Therapeutics raised $4.3M (Seed) on August 24, 2021.
- Akari Therapeutics raised $12M on July 22, 2021.
- Arzeda raised $26M on July 22, 2021.
- Kriya Therapeutics raised $100M (Series B) on July 14, 2021.
- Kriya Therapeutics raised $321M on July 14, 2021.
- Scientific Industries raised $9.5M on July 1, 2021.
Who to call at Wugen, and when
A new round usually means Wugen is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Wugen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Wugen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Wugen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Wugen raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Wugen raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.